Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis)

Maria Esposito^#¹, Paolo Gisondi^#², Chiara Assorgi^{3

4}, Francesco Bellinato², Pina Brianti⁵, Martina Burlando⁶, Giovanna Brunasso⁷, Stefano Caccavale⁸, Giacomo Caldarola⁹, Elena Campione¹⁰, Piergiacomo Calzavara Pinton¹¹, Anna Campanati¹², Carlo Giovanni Carrera¹³, Andrea Carugno^{14

15}, Emanuele Cozzani⁶, Antonio Costanzo¹⁶, Francesco Cusano¹⁷, Paolo Dapavo¹⁸, Annunziata Dattola¹⁹, Clara De Simone⁹, Roberta Di Caprio⁸, Federico Diotallevi¹², Maria Concetta Fargnoli²⁰, Francesca Gaiani²¹, Alessandro Giunta¹⁰, Piergiorgio Malagoli²¹, Angelo Valerio Marzano^{13

22}, Matteo Megna⁴, Santo Raffaele Mercuri⁵, Edoardo Mortato²³, Alessandra Narcisi¹⁶, Diego Orsini³, Luca Potestio⁴, Pietro Quaglino¹⁸, Antonio Giovanni Richetta¹⁹, Francesca Romano²⁴, Paolo Sena¹⁴, Emanuele Vagnozzi²⁰, Marina Venturini¹¹, Francesco Loconsole^#²³, Anna Balato^#⁸

Affiliations

¹ Department of Biotechnological ad Applied Clinical Sciences, University of L'Aquila, via Vetoio-Coppito 2, 67100, L'Aquila, Italy. maria.esposito3@univaq.it.
² Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
³ Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
⁴ Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
⁵ Unit of Dermatology and Cosmetology, Vita-Salute San Raffaele University and Institute for Research and Care, Milan, Italy.
⁶ Section of Dermatology, Department of Health Sciences (DISSAL), IRCCS San Martino University Hospital, Genoa, Italy.
⁷ Department of Dermatology, Galliera Hospital, Genova, Italy.
⁸ Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
⁹ Section of Dermatology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy.
¹⁰ Department of Dermatology, University of Rome 'Tor Vergata', Rome, Italy.
¹¹ Department of Dermatology, University of Brescia, ASST Spedali Civili, Brescia, Italy.
¹² Dermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy.
¹³ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
¹⁴ Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
¹⁵ Ph.D. Program in Molecular and Translational Medicine (DIMET), University of Milan-Bicocca, Milan, Italy.
¹⁶ Dermatology Unit, IRCCS Humanitas Clinical and Research Center, Rozzano (Milan), Italy.
¹⁷ Department of Dermatology, Gaetano Rummo Hospital, Benevento, Italy.
¹⁸ Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.
¹⁹ Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy.
²⁰ Department of Biotechnological ad Applied Clinical Sciences, University of L'Aquila, via Vetoio-Coppito 2, 67100, L'Aquila, Italy.
²¹ Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.
²² Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
²³ Department of Dermatology, University of Bari, Piazza Umberto I, 1, 70121, Bari, Italy.
²⁴ Dermatology Unit, AORN "A. Cardarelli", Naples, Italy.

^# Contributed equally.

PMID: 40372625
PMCID: PMC12144061
DOI: 10.1007/s40261-025-01440-z

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis)

Maria Esposito et al. Clin Drug Investig. 2025 Jun.

. 2025 Jun;45(6):309-315.

doi: 10.1007/s40261-025-01440-z. Epub 2025 May 15.

Authors

Affiliations

¹ Department of Biotechnological ad Applied Clinical Sciences, University of L'Aquila, via Vetoio-Coppito 2, 67100, L'Aquila, Italy. maria.esposito3@univaq.it.
² Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
³ Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
⁴ Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
⁵ Unit of Dermatology and Cosmetology, Vita-Salute San Raffaele University and Institute for Research and Care, Milan, Italy.
⁶ Section of Dermatology, Department of Health Sciences (DISSAL), IRCCS San Martino University Hospital, Genoa, Italy.
⁷ Department of Dermatology, Galliera Hospital, Genova, Italy.
⁸ Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
⁹ Section of Dermatology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy.
¹⁰ Department of Dermatology, University of Rome 'Tor Vergata', Rome, Italy.
¹¹ Department of Dermatology, University of Brescia, ASST Spedali Civili, Brescia, Italy.
¹² Dermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy.
¹³ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
¹⁴ Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
¹⁵ Ph.D. Program in Molecular and Translational Medicine (DIMET), University of Milan-Bicocca, Milan, Italy.
¹⁶ Dermatology Unit, IRCCS Humanitas Clinical and Research Center, Rozzano (Milan), Italy.
¹⁷ Department of Dermatology, Gaetano Rummo Hospital, Benevento, Italy.
¹⁸ Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.
¹⁹ Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy.
²⁰ Department of Biotechnological ad Applied Clinical Sciences, University of L'Aquila, via Vetoio-Coppito 2, 67100, L'Aquila, Italy.
²¹ Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.
²² Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
²³ Department of Dermatology, University of Bari, Piazza Umberto I, 1, 70121, Bari, Italy.
²⁴ Dermatology Unit, AORN "A. Cardarelli", Naples, Italy.

^# Contributed equally.

PMID: 40372625
PMCID: PMC12144061
DOI: 10.1007/s40261-025-01440-z

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: None. Conflicts of Interest: M. Esposito has served as a speaker/board member for Abbvie, Almirall, Eli Lilly, Janssen, Leo Pharma, Novartis, Sanofi, UCB. A. Balato has received honoraria for participation in advisory boards, meetings, or as a speaker for AbbVie, Celgene, Janssen-Cilag, Eli Lilly, Novartis Pharma, Pfizer, Sanofi-Genzyme, and UCB Pharma. P. Malagoli has been a speaker for AbbVie, Lilly, Novartis, Janssen-Cilag, Celgene, Leopharma, and Almirall. G. Caldarola reports consulting fees or honorarium and payment for lectures from Lilly and Novartis. P. Gisondi has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, Leo-Pharma, Eli-Lilly, Novartis, Pierre Febre, Sandoz, Sanofi, and UCB. C. Carrera has served as a board participant or speaker for Abbvie, Lilly, Janssen, Novartis, Celgene, Almirall, and Leopharma. P. Dapavo has been a speaker for Novartis, Abbvie, Sanofi, UCB, Janssen, Lilly, and LeoPharma. F. Gaiani acted as a speaker or consultant for Novartis, Abbvie, Eli Lilly, Celgene, LeoPharma, and Almirall. A.Giunta received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Celgene, Janssen, Leo Pharma, Eli Lilly, Merck Sharpe Dohme, Novartis, Pfizer, Sandoz, and UCB. F.Loconsole served on advisory boards and/ or received honoraria for lectures from Abbvie, Janssen-Cilag, Novartis, Lilly, Sanofi. A.V. Marzano reports consultancy/advisory board disease-relevant honoraria from AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi and UCB. M. Megna has served as a speaker/board member for Abbvie, Almirall, Amgen, Eli Lilly, Janssen, Leo Pharma, Novartis, UCB. M. Venturini served as a speaker or advisory board member for Abbvie, Almirall, Amgen, Eli-Lilly, Galderma, Leo Pharma, Novartis, Pierre Fabre, and UCB Pharma. A. Costanzo has served as an advisory board member, consultant and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB-Pharma. A. Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen, and Boehringer Ingelheim. A. Carugno has served as a speaker/board member for Abbvie, Almirall, Boehringer Ingelheim, Eli Lilly, Janssen, Leo Pharma, Novartis, UCB Pharma. C. De Simone served as a speaker or advisory board member for Almirall, AbbVie, Amgen, Eli Lilly, Janssen, Leopharma, Novartis, Sanofi and UCB Pharma. M.C. Fargnoli has served on advisory boards, received honoraria for lectures and/or research grants from AMGEN, Almirall, Abbvie, Boehringer-Ingelheim, BMS, Galderma, Kyowa Kyrin, Leo Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi-Regeneron, Sunpharma. M. Burlando. served as a speaker or advisory board member for Almirall, AbbVie, Amgen, Eli Lilly, Janssen, Leopharma, Novartis, and UCB Pharma. D. Orsini has been a speaker and/or consultant for Abbvie, LeoPharma, UCB, Bristol-Meyer Squibb and Boehringer-Ingelheim. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Ethics Approval: Patients signed an informed consent to allow collection and utilization of clinical data for scientific purposes. This study adhered to established standards of good clinical practice. Ethical approvation number 0006349 was obtained from the Comitato Etico Territoriale (CET) Interaziendale AOU Città della Salute e della Scienza di Torino. Consent to Participate: All patients gave written informed consent for the retrospective retrieval of anonymized data. All patients gave written informed consent for the pubblication of anonymized data. Consent for Publication: Not applicable. Availability of Data and Material: Additional data supporting the findings of this study are avaiabile from the corresponduing author on reasonable request. Code Availability: Not applicable. Authors'Contributions: Study conception and design: Maria Esposito, Paolo Gisondi, Chiara Assorgi, Francesco Bellinato, Pina Brianti, Martina Burlando, Giovanna Brunasso, Stefano Caccavale, Giacomo Caldarola, Elena Campione, Piergiacomo Calzavara Pinton, Anna Campanati, Carlo Giovanni Carrera, Andrea Carugno, Emanuele Cozzani, Antonio Costanzo, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Roberta Di Caprio, Federico Diotallevi, Maria Concetta Fargnoli, Francesca Gaiani, Alessandro Giunta, Piergiorgio Malagoli, Angelo Valerio Marzano, Matteo Megna, Santo Raffaele Mercuri, Edoardo Mortato, Alessandra Narcisi, Diego Orsini, Luca Potestio, Pietro Quaglino, Antonio Giovanni Richetta, Francesca Romano, Paolo Sena, Emanuele Vagnozzi, Marina Venturini, Francesco Loconsole, Anna Balato; manuscprit editing: Maria Esposito, Paolo Gisondi, Francesco Loconsole, Anna Balato; approval to submit: Maria Esposito, Paolo Gisondi, Francesco Loconsole, Anna Balato.

Figures

**Fig. 1**
Bimekizumab clinical effectiveness as assessed by Psoriasis Area Severity Index (PASI) 75, PASI 90, and PASI 100 at week 4 (A) and week 16 (B)

**Fig. 2**
Results of the multivariable logistic regression model at week 16

See this image and copyright information in PMC

References

1. Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, et al. Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med. 2021;385(2):130–41. 10.1056/NEJMoa2102388. (Epub 2021 Apr 23). - PubMed
1. Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–86. 10.1016/S0140-6736(21)00126-4. (Erratum in: Lancet. 2021 Mar 27;397(10280):1182. 10.1016/S0140-6736(21)00669-3). - PubMed
1. Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–98. 10.1016/S0140-6736(21)00125-2. (Erratum in: Lancet. 2021 Feb 20;397(10275):670. 10.1016/S0140-6736(21)00387-1). - PubMed
1. Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med. 2021;385(2):142–52. 10.1056/NEJMoa2102383. (Epub 2021 Apr 23). - PubMed
1. Talamonti M, D’Adamio S, Galluccio T, Andreani M, Pastorino R, Egan CG, et al. High-resolution HLA typing identifies a new “super responder” subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab. J Eur Acad Dermatol Venereol. 2019;33(10):e364–7. 10.1111/jdv.15659. (Epub 2019 May 20). - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis)

Affiliations

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis)

Authors

Affiliations

Conflict of interest statement

Figures

References

Publication types

LinkOut - more resources

Full Text Sources